{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T14:36:18Z","timestamp":1782916578449,"version":"3.54.5"},"reference-count":27,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2016,3,1]],"date-time":"2016-03-01T00:00:00Z","timestamp":1456790400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalkey.jp","clinicalkey.com","clinical-lymphoma-myeloma-leukemia.com","clinicalkey.es","clinicalkey.com.au","clinicalkey.fr","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Lymphoma Myeloma and Leukemia"],"published-print":{"date-parts":[[2016,3]]},"DOI":"10.1016\/j.clml.2015.12.001","type":"journal-article","created":{"date-parts":[[2015,12,20]],"date-time":"2015-12-20T09:45:18Z","timestamp":1450604718000},"page":"169-174","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":40,"title":["Imatinib Increases Serum Creatinine by Inhibiting Its Tubular Secretion in a Reversible Fashion in Chronic Myeloid Leukemia"],"prefix":"10.1016","volume":"16","author":[{"given":"Emmanuelle","family":"Vidal-Petiot","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Delphine","family":"Rea","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fid\u00e9line","family":"Serrano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas","family":"Stehl\u00e9","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Claude","family":"Gardin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Philippe","family":"Rousselot","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marie-No\u00eblle","family":"Peraldi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martin","family":"Flamant","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.clml.2015.12.001_bib1","doi-asserted-by":"crossref","first-page":"872","DOI":"10.1182\/blood-2013-05-501569","article-title":"European LeukemiaNet recommendations for the management of chronic myeloid leukemia: 2013","volume":"122","author":"Baccarani","year":"2013","journal-title":"Blood"},{"key":"10.1016\/j.clml.2015.12.001_bib2","doi-asserted-by":"crossref","first-page":"1637","DOI":"10.1200\/JCO.2003.11.143","article-title":"Practical management of patients with chronic myeloid leukemia receiving imatinib","volume":"21","author":"Deininger","year":"2003","journal-title":"J\u00a0Clin Oncol"},{"issue":"Suppl 2","key":"10.1016\/j.clml.2015.12.001_bib3","doi-asserted-by":"crossref","first-page":"S149","DOI":"10.1007\/s00277-015-2318-y","article-title":"Management of adverse events associated with tyrosine kinase inhibitors in chronic myeloid leukemia","volume":"94","author":"Rea","year":"2015","journal-title":"Ann Hematol"},{"key":"10.1016\/j.clml.2015.12.001_bib4","doi-asserted-by":"crossref","first-page":"2408","DOI":"10.1056\/NEJMoa062867","article-title":"Five-year follow-up of patients receiving imatinib for chronic myeloid leukemia","volume":"355","author":"Druker","year":"2006","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.clml.2015.12.001_bib5","doi-asserted-by":"crossref","first-page":"553","DOI":"10.1093\/jnci\/djr060","article-title":"Multicenter independent assessment of outcomes in chronic myeloid leukemia patients treated with imatinib","volume":"103","author":"Gambacorti-Passerini","year":"2011","journal-title":"J\u00a0Natl Cancer Inst"},{"key":"10.1016\/j.clml.2015.12.001_bib6","doi-asserted-by":"crossref","first-page":"1123","DOI":"10.1038\/leu.2015.36","article-title":"Safety and efficacy of imatinib in CML over a period of 10 years: data from the randomized CML-study IV","volume":"29","author":"Kalmanti","year":"2015","journal-title":"Leukemia"},{"key":"10.1016\/j.clml.2015.12.001_bib7","doi-asserted-by":"crossref","first-page":"2073","DOI":"10.1093\/annonc\/mdq715","article-title":"Imatinib treatment duration is related to decreased estimated glomerular filtration rate in chronic myeloid leukemia patients","volume":"22","author":"Marcolino","year":"2011","journal-title":"Ann Oncol"},{"key":"10.1016\/j.clml.2015.12.001_bib8","doi-asserted-by":"crossref","first-page":"3894","DOI":"10.1002\/cncr.29587","article-title":"Estimated glomerular filtration rate changes in patients with chronic myeloid leukemia treated with tyrosine kinase inhibitors","volume":"121","author":"Yilmaz","year":"2015","journal-title":"Cancer"},{"key":"10.1016\/j.clml.2015.12.001_bib9","doi-asserted-by":"crossref","first-page":"604","DOI":"10.7326\/0003-4819-150-9-200905050-00006","article-title":"A\u00a0new equation to estimate glomerular filtration rate","volume":"150","author":"Levey","year":"2009","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.clml.2015.12.001_bib10","doi-asserted-by":"crossref","first-page":"461","DOI":"10.7326\/0003-4819-130-6-199903160-00002","article-title":"A\u00a0more accurate method to estimate glomerular filtration rate from serum creatinine: a new prediction equation. Modification of Diet in Renal Disease Study Group","volume":"130","author":"Levey","year":"1999","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.clml.2015.12.001_bib11","first-page":"19","article-title":"KDIGO 2012 clinical practice guideline for the evaluation and management of chronic kidney disease. Chapter 1: Definition and classification of CKD","volume":"3","year":"2013","journal-title":"Kidney Int Suppl"},{"key":"10.1016\/j.clml.2015.12.001_bib12","doi-asserted-by":"crossref","first-page":"763","DOI":"10.1681\/ASN.2004070549","article-title":"Predictive performance of the modification of diet in renal disease and Cockcroft-Gault equations for estimating renal function","volume":"16","author":"Froissart","year":"2005","journal-title":"J\u00a0Am Soc Nephrol"},{"key":"10.1016\/j.clml.2015.12.001_bib13","unstructured":"ImatinibAccord,INN-imatinib-WC500145561.pdf. Available at: http:\/\/www.ema.europa.eu\/docs\/en_GB\/document_library\/EPAR_-_Summary_for_the_public\/human\/002681\/WC500145561.pdf. Accessed July 23, 2015."},{"key":"10.1016\/j.clml.2015.12.001_bib14","doi-asserted-by":"crossref","first-page":"350","DOI":"10.1038\/ki.2014.66","article-title":"Contribution of the organic anion transporter OAT2 to the renal active tubular secretion of creatinine and mechanism for serum creatinine elevations caused by cobicistat","volume":"86","author":"Lepist","year":"2014","journal-title":"Kidney Int"},{"key":"10.1016\/j.clml.2015.12.001_bib15","doi-asserted-by":"crossref","first-page":"976","DOI":"10.1023\/B:PHAM.0000029286.45788.ad","article-title":"Creatinine transport by basolateral organic cation transporter hOCT2 in the human kidney","volume":"21","author":"Urakami","year":"2004","journal-title":"Pharm Res"},{"key":"10.1016\/j.clml.2015.12.001_bib16","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1046\/j.1365-2796.1999.00515.x","article-title":"A\u00a0rise in plasma creatinine that is not a sign of renal failure: which drugs can be responsible?","volume":"246","author":"Andreev","year":"1999","journal-title":"J\u00a0Intern Med"},{"key":"10.1016\/j.clml.2015.12.001_bib17","first-page":"802","article-title":"Effect of trimethoprim-sulfamethoxazole on the renal excretion of creatinine in man","volume":"114","author":"Berglund","year":"1975","journal-title":"J\u00a0Urol"},{"key":"10.1016\/j.clml.2015.12.001_bib18","doi-asserted-by":"crossref","first-page":"1326","DOI":"10.1016\/0140-6736(92)92502-7","article-title":"Creatinine clearance during cimetidine administration for measurement of glomerular filtration rate","volume":"340","author":"van Acker","year":"1992","journal-title":"Lancet"},{"key":"10.1016\/j.clml.2015.12.001_bib19","first-page":"199","article-title":"Renal tubular transporter-mediated interactions of HIV drugs: implications for patient management","volume":"16","author":"Guti\u00e9rrez","year":"2014","journal-title":"AIDS Rev"},{"key":"10.1016\/j.clml.2015.12.001_bib20","first-page":"144","article-title":"Novel antiretroviral drugs and renal function monitoring of HIV patients","volume":"16","author":"Maggi","year":"2014","journal-title":"AIDS Rev"},{"key":"10.1016\/j.clml.2015.12.001_bib21","doi-asserted-by":"crossref","first-page":"1263","DOI":"10.1016\/j.bcp.2009.06.014","article-title":"Protective effect of concomitant administration of imatinib on cisplatin-induced nephrotoxicity focusing on renal organic cation transporter OCT2","volume":"78","author":"Tanihara","year":"2009","journal-title":"Biochem Pharmacol"},{"key":"10.1016\/j.clml.2015.12.001_bib22","doi-asserted-by":"crossref","first-page":"531","DOI":"10.1158\/1535-7163.MCT-10-0731","article-title":"Interactions of tyrosine kinase inhibitors with organic cation transporters and multidrug and toxic compound extrusion proteins","volume":"10","author":"Minematsu","year":"2011","journal-title":"Mol Cancer Ther"},{"key":"10.1016\/j.clml.2015.12.001_bib23","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1038\/ki.1990.182","article-title":"Measurement of renal function in chronic renal disease","volume":"38","author":"Levey","year":"1990","journal-title":"Kidney Int"},{"key":"10.1016\/j.clml.2015.12.001_bib24","doi-asserted-by":"crossref","first-page":"830","DOI":"10.1038\/ki.1985.205","article-title":"Limitations of creatinine as a filtration marker in glomerulopathic patients","volume":"28","author":"Shemesh","year":"1985","journal-title":"Kidney Int"},{"key":"10.1016\/j.clml.2015.12.001_bib25","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1056\/NEJMoa1114248","article-title":"Estimating glomerular filtration rate from serum creatinine and cystatin C","volume":"367","author":"Inker","year":"2012","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.clml.2015.12.001_bib26","doi-asserted-by":"crossref","first-page":"F997","DOI":"10.1152\/ajprenal.00431.2009","article-title":"Human multidrug and toxin extrusion 1 (MATE1\/SLC47A1) transporter: functional characterization, interaction with OCT2 (SLC22A2), and single nucleotide polymorphisms","volume":"298","author":"Meyer zu Schwabedissen","year":"2010","journal-title":"Am J Physiol Renal Physiol"},{"key":"10.1016\/j.clml.2015.12.001_bib27","doi-asserted-by":"crossref","first-page":"581","DOI":"10.1208\/s12248-013-9465-7","article-title":"Organic cation transporter OCTs (SLC22) and MATEs (SLC47) in the human kidney","volume":"15","author":"Motohashi","year":"2013","journal-title":"AAPS J"}],"container-title":["Clinical Lymphoma Myeloma and Leukemia"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2152265015014147?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2152265015014147?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2018,9,16]],"date-time":"2018-09-16T14:54:07Z","timestamp":1537109647000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2152265015014147"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,3]]},"references-count":27,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2016,3]]}},"alternative-id":["S2152265015014147"],"URL":"https:\/\/doi.org\/10.1016\/j.clml.2015.12.001","relation":{},"ISSN":["2152-2650"],"issn-type":[{"value":"2152-2650","type":"print"}],"subject":[],"published":{"date-parts":[[2016,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Imatinib Increases Serum Creatinine by Inhibiting Its Tubular Secretion in a Reversible Fashion in Chronic Myeloid Leukemia","name":"articletitle","label":"Article Title"},{"value":"Clinical Lymphoma Myeloma and Leukemia","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.clml.2015.12.001","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2016 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}